Nucleoside phosphoramidates
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
1. A compound represented by the formula (4):
wherein P* represents a chiral phosphorus atom and wherein the compound is at least 97% of the S P stereoisomer represented by the formula (S P -4):
and not more than 3% of the R P stereoisomer represented by the formula (R P -4):
2. The compound according to claim 1 , wherein the compound is at least 98% of the S P stereoisomer represented by the formula (S P -4) and not more than 2% of the R P stereoisomer represented by the formula (R P -4).
3. The compound according to claim 1 , wherein the compound is at least 99% of the S P stereoisomer represented by the formula (S P -4) and not more than 1% of the R P stereoisomer represented by the formula (R P -4).
4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable medium.
5. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable medium.
6. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable medium.
7. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 1 .
8. The method according to claim 7 further comprising administering to the human another antiviral agent.
9. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 2 .
10. The method according to claim 9 further comprising administering to the human another antiviral agent.
11. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 3 .
12. The method according to claim 11 further comprising administering to the human another antiviral agent.